Skip to main content
Fig. 9 | Cancer Nanotechnology

Fig. 9

From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 9

Graph A shows the mean of WBC, neutrophil, and lymphocyte count at days 0, 0.5, and 7 in immunosuppressant animals, and graph B represents the whole protocol mean WBC, neutrophil and lymphocyte count of control and immunosuppressed rats after cyclophosphamide treatment (n = 10, mean ± SD, p ≤ 0.05)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us